TerrAscend (TSNDF) FCF Payout Ratio (2022 - 2023)
TerrAscend's (TSNDF) quarterly FCF Payout Ratio came in at 3.82 in Q4 2023, down 58917.75% year-on-year from N/an in Q4 2022, and down 1070.2% on a QoQ basis from 0.39 in Q3 2023.
TerrAscend (TSNDF) FCF Payout Ratio (2022 - 2023) Analysis & Trends
TerrAscend (TSNDF) has 2 years of FCF Payout Ratio data on file, last reported at 3.82 in Q4 2023.
- On a quarterly basis, FCF Payout Ratio fell 58917.75% year-over-year to 3.82 in Q4 2023; TTM through Dec 2023 was 0.15, a N/A change from a year earlier, with the FY2022 full-year figure at 0.03, changed N/A from the prior year.
- FCF Payout Ratio for Q4 2023 stood at 3.82, down from 0.39 in the prior quarter.
- Over the last five years, FCF Payout Ratio for TSNDF reached as high as 0.39 in Q3 2023 and fell as low as 3.82 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.77 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -10.50 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.40 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -3.82 |
| Sep 30, 2023 | 0.39 |
| Dec 31, 2022 | -0.01 |